GTCR Commits Up To $200M To Specialty Pharma Venture
Chicago private equity firm GTCR will pour up to $200 million into Crealta Pharmaceuticals Inc., a specialty pharmaceuticals upstart with an eye toward climbing to a top spot in the buzzing...To view the full article, register now.
Already a subscriber? Click here to view full article